Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets

Nat Commun. 2023 Sep 27;14(1):6030. doi: 10.1038/s41467-023-41442-z.

Abstract

Influenza A Virus (IAV) is a recurring respiratory virus with limited availability of antiviral therapies. Understanding host proteins essential for IAV infection can identify targets for alternative host-directed therapies (HDTs). Using affinity purification-mass spectrometry and global phosphoproteomic and protein abundance analyses using three IAV strains (pH1N1, H3N2, H5N1) in three human cell types (A549, NHBE, THP-1), we map 332 IAV-human protein-protein interactions and identify 13 IAV-modulated kinases. Whole exome sequencing of patients who experienced severe influenza reveals several genes, including scaffold protein AHNAK, with predicted loss-of-function variants that are also identified in our proteomic analyses. Of our identified host factors, 54 significantly alter IAV infection upon siRNA knockdown, and two factors, AHNAK and coatomer subunit COPB1, are also essential for productive infection by SARS-CoV-2. Finally, 16 compounds targeting our identified host factors suppress IAV replication, with two targeting CDK2 and FLT3 showing pan-antiviral activity across influenza and coronavirus families. This study provides a comprehensive network model of IAV infection in human cells, identifying functional host targets for pan-viral HDT.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antiviral Agents / metabolism
  • COVID-19*
  • Host-Pathogen Interactions / genetics
  • Humans
  • Influenza A Virus, H3N2 Subtype / metabolism
  • Influenza A Virus, H5N1 Subtype* / genetics
  • Influenza A virus* / genetics
  • Influenza, Human* / genetics
  • Proteomics
  • SARS-CoV-2
  • Virus Replication / genetics

Substances

  • Antiviral Agents